Home » Stocks » RLMD

Relmada Therapeutics, Inc. (RLMD)

Stock Price: $37.13 USD -0.54 (-1.43%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 630.87M
Revenue (ttm) n/a
Net Income (ttm) -59.46M
Shares Out 15.59M
EPS (ttm) -3.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $37.13
Previous Close $37.67
Change ($) -0.54
Change (%) -1.43%
Day's Open 37.53
Day's Range 36.74 - 37.82
Day's Volume 50,825
52-Week Range 28.40 - 54.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 6, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will ...

46 minutes ago - PRNewsWire

NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical...

5 days ago - PRNewsWire

NEW YORK, April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data ...

1 week ago - PRNewsWire

NEW YORK, April 28, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergi...

1 week ago - PRNewsWire

NEW YORK, April 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data ...

1 week ago - PRNewsWire

NEW YORK, April 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiat...

1 month ago - PRNewsWire

NEW YORK, March 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate...

1 month ago - PRNewsWire

NEW YORK, March 18, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it wi...

1 month ago - PRNewsWire

NEW YORK, March 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergi...

1 month ago - PRNewsWire

Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the fir...

4 months ago - PRNewsWire

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, NLTX, PRGO, SNY, SUPN ...
7 months ago - Investopedia

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

8 months ago - PRNewsWire

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Other stocks mentioned: DRRX, NLTX
9 months ago - The Motley Fool

NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today an...

11 months ago - PRNewsWire

NEW YORK, May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today an...

11 months ago - PRNewsWire

Should investors be excited or concerned about Relmada Therapeutics' attempt to treat severe depression with a variant of methadone?

11 months ago - The Motley Fool

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2.

Other stocks mentioned: GILD, TCNNF
1 year ago - Investopedia

Relmada Therapeutics: A Promising Depression Focused Player For 2020

1 year ago - Seeking Alpha

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1.

Other stocks mentioned: TCNNF
1 year ago - Investopedia

Relmada Therapeutics Inc. shares RLMD, +141.79% soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression.

1 year ago - Market Watch

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid an... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2004
CEO
Sergio Traversa
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
RLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price forecast is 63.67, which is an increase of 71.48% from the latest price.

Price Target
$63.67
(71.48% upside)
Analyst Consensus: Strong Buy